These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 28498840

  • 1. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, Wiggins R, Di Marco S, Colloca S, Siani L, Cortese R, Smith DF, Aebischer T, Kaye PM, Lacey CJ.
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.
    Younis BM, Osman M, Khalil EAG, Santoro F, Furini S, Wiggins R, Keding A, Carraro M, Musa AEA, Abdarahaman MAA, Mandefield L, Bland M, Aebischer T, Gabe R, Layton AM, Lacey CJN, Kaye PM, Musa AM.
    Mol Ther; 2021 Jul 07; 29(7):2366-2377. PubMed ID: 33781913
    [Abstract] [Full Text] [Related]

  • 3. LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.
    Lacey C, Musa A, Khalil ET, Younis B, Osman M, Wiggins R, Keding A, Kaye P.
    Wellcome Open Res; 2022 Jul 07; 7():200. PubMed ID: 37252616
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis.
    Younis BM, Wiggins R, Khalil EAG, Osman M, Santoro F, Sonnati C, Keding A, Novedrati M, Montesi G, Noureldein A, Elmukashfi ETA, Mustafa AE, Alamin M, Saeed M, Salman K, Suliman AJ, Musa AEA, Layton AM, Lacey CJN, Kaye PM, Musa AM.
    Mol Ther Methods Clin Dev; 2024 Sep 12; 32(3):101310. PubMed ID: 39253357
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.
    Kaushal H, Bras-Gonçalves R, Avishek K, Kumar Deep D, Petitdidier E, Lemesre JL, Papierok G, Kumar S, Ramesh V, Salotra P.
    Clin Exp Immunol; 2016 Jul 12; 185(1):50-60. PubMed ID: 26948150
    [Abstract] [Full Text] [Related]

  • 6. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.
    Ganguly S, Das NK, Panja M, Pal S, Modak D, Rahaman M, Mallik S, Guha SK, Pramanik N, Goswami R, Barbhuiya JN, Saha B, Chatterjee M.
    J Infect Dis; 2008 Jun 15; 197(12):1762-71. PubMed ID: 18444882
    [Abstract] [Full Text] [Related]

  • 7. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis.
    Ganguly S, Mukhopadhyay D, Das NK, Chaduvula M, Sadhu S, Chatterjee U, Rahman M, Goswami RP, Guha SK, Modak D, Mallik S, Gonju D, Pramanik N, Barbhuiya JN, Saha B, Chatterjee M.
    J Invest Dermatol; 2010 Apr 15; 130(4):1013-22. PubMed ID: 20032994
    [Abstract] [Full Text] [Related]

  • 8. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.
    PLoS Negl Trop Dis; 2011 Jun 15; 5(6):e1204. PubMed ID: 21695103
    [Abstract] [Full Text] [Related]

  • 9. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
    Zijlstra EE.
    Parasit Vectors; 2016 Aug 23; 9(1):464. PubMed ID: 27553063
    [Abstract] [Full Text] [Related]

  • 10. The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC).
    Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG.
    Clin Exp Immunol; 2000 Mar 23; 119(3):523-9. PubMed ID: 10691926
    [Abstract] [Full Text] [Related]

  • 11. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
    Saha S, Mazumdar T, Anam K, Ravindran R, Bairagi B, Saha B, Goswami R, Pramanik N, Guha SK, Kar S, Banerjee D, Ali N.
    J Clin Microbiol; 2005 Mar 23; 43(3):1269-77. PubMed ID: 15750095
    [Abstract] [Full Text] [Related]

  • 12. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
    Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gilleman Q, Thunissen C, Hinckel BCB, Pearson C, Gardner BL, Airs S, de la Roche M, Hayes K, Hafezi H, Falconar AK, Eisa O, Saad A, Khanal B, Bhattarai NR, Rijal S, Boelaert M, El-Safi S, Sundar S, Miles MA.
    Front Cell Infect Microbiol; 2018 Mar 23; 8():427. PubMed ID: 30619774
    [Abstract] [Full Text] [Related]

  • 13. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM, Leishmaniasis Research Group/Sudan.
    Trans R Soc Trop Med Hyg; 2008 Jan 23; 102(1):58-63. PubMed ID: 17963805
    [Abstract] [Full Text] [Related]

  • 14. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
    Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O.
    Vaccine; 2009 Feb 11; 27(7):1080-6. PubMed ID: 19095029
    [Abstract] [Full Text] [Related]

  • 15. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.
    Salih MA, Fakiola M, Abdelraheem MH, Younis BM, Musa AM, ElHassan AM, Blackwell JM, Ibrahim ME, Mohamed HS.
    BMC Infect Dis; 2014 Dec 03; 14():662. PubMed ID: 25466928
    [Abstract] [Full Text] [Related]

  • 16. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.
    Trop Med Int Health; 2012 Nov 03; 17(11):1345-8. PubMed ID: 22882665
    [Abstract] [Full Text] [Related]

  • 17. Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.
    Avishek K, Kaushal H, Gannavaram S, Dey R, Selvapandiyan A, Ramesh V, Negi NS, Dubey US, Nakhasi HL, Salotra P.
    Sci Rep; 2016 Sep 14; 6():33059. PubMed ID: 27624408
    [Abstract] [Full Text] [Related]

  • 18. Transcriptome Analysis of Dermal Fibroblasts Derived From Visceral Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis Patients Reveal Disease-Specific Gene Expression and Pathological Regulation.
    Singh S, Madhukar M, Dikhit MR, Ravidas VN, Pandey K, Sen A.
    J Infect Dis; 2023 May 12; 227(10):1132-1142. PubMed ID: 36821723
    [Abstract] [Full Text] [Related]

  • 19. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
    Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, Kharazmi A, Theander TG.
    J Pathol; 1999 Dec 12; 189(4):615-22. PubMed ID: 10629566
    [Abstract] [Full Text] [Related]

  • 20. In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis.
    Sengupta R, Mukherjee S, Moulik S, Mitra S, Chaudhuri SJ, Das NK, Chatterjee U, Chatterjee M.
    Int J Parasitol Drugs Drug Resist; 2019 Dec 12; 11():166-176. PubMed ID: 31542359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.